175 related articles for article (PubMed ID: 28139960)
1. Development of an In Vitro Model to Screen CYP1B1-Targeted Anticancer Prodrugs.
Wang Z; Chen Y; Drbohlav LM; Wu JQ; Wang MZ
J Biomol Screen; 2016 Dec; 21(10):1090-1099. PubMed ID: 28139960
[TBL] [Abstract][Full Text] [Related]
2. The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells.
Ruparelia KC; Zeka K; Ijaz T; Ankrett DN; Wilsher NE; Butler PC; Tan HL; Lodhi S; Bhambra AS; Potter GA; Arroo RRJ; Beresford KJM
Med Chem; 2018; 14(4):322-332. PubMed ID: 29332599
[TBL] [Abstract][Full Text] [Related]
3. DMAKO-20 as a New Multitarget Anticancer Prodrug Activated by the Tumor Specific CYP1B1 Enzyme.
Cui J; Zhang X; Huang G; Zhang Q; Dong J; Sun G; Meng Q; Li S
Mol Pharm; 2019 Jan; 16(1):409-421. PubMed ID: 30481041
[TBL] [Abstract][Full Text] [Related]
4. The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells.
Ruparelia KC; Lodhi S; Ankrett DN; Wilsher NE; Arroo RRJ; Potter GA; Beresford KJM
Bioorg Med Chem Lett; 2019 Jun; 29(11):1403-1406. PubMed ID: 30935796
[TBL] [Abstract][Full Text] [Related]
5. CYP1B1: A Promising Target in Cancer Drug Discovery.
Fabris M; Luiza Silva M; de Santiago-Silva KM; de Lima Ferreira Bispo M; Goes Camargo P
Anticancer Agents Med Chem; 2023; 23(9):981-988. PubMed ID: 36655529
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer.
Presa D; Khurram SA; Zubir AZA; Smarakan S; Cooper PA; Morais GR; Sadiq M; Sutherland M; Loadman PM; McCaul J; Shnyder SD; Patterson LH; Pors K
Sci Rep; 2021 Sep; 11(1):18930. PubMed ID: 34556703
[TBL] [Abstract][Full Text] [Related]
7. Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression.
Cui J; Meng Q; Zhang X; Cui Q; Zhou W; Li S
J Med Chem; 2015 Apr; 58(8):3534-47. PubMed ID: 25799264
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models.
Laroche-Clary A; Le Morvan V; Yamori T; Robert J
Mol Cancer Ther; 2010 Dec; 9(12):3315-21. PubMed ID: 20889730
[TBL] [Abstract][Full Text] [Related]
9. α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship.
Chen P; Wang S; Cao C; Ye W; Wang M; Zhou C; Chen W; Zhang X; Zhang K; Zhou W
Bioorg Chem; 2021 Nov; 116():105295. PubMed ID: 34455300
[TBL] [Abstract][Full Text] [Related]
10. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance.
Sonawane VR; Siddique MUM; Gatchie L; Williams IS; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
Eur J Pharm Sci; 2019 Apr; 131():177-194. PubMed ID: 30776468
[TBL] [Abstract][Full Text] [Related]
11. Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme.
Sharma R; Gatchie L; Williams IS; Jain SK; Vishwakarma RA; Chaudhuri B; Bharate SB
Bioorg Med Chem Lett; 2017 Dec; 27(24):5400-5403. PubMed ID: 29150398
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 1B1: a novel anticancer therapeutic target.
McFadyen MC; Murray GI
Future Oncol; 2005 Apr; 1(2):259-63. PubMed ID: 16555997
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation.
Chang I; Mitsui Y; Kim SK; Sun JS; Jeon HS; Kang JY; Kang NJ; Fukuhara S; Gill A; Shahryari V; Tabatabai ZL; Greene KL; Dahiya R; Shin DM; Tanaka Y
Oncotarget; 2017 Jun; 8(24):39087-39100. PubMed ID: 28388569
[TBL] [Abstract][Full Text] [Related]
14. Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.
Su J; Gu Y; Pruijn FB; Smaill JB; Patterson AV; Guise CP; Wilson WR
J Biol Chem; 2013 Dec; 288(52):37138-53. PubMed ID: 24196959
[TBL] [Abstract][Full Text] [Related]
15. The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cells.
Husbeck B; Powis G
Carcinogenesis; 2002 Oct; 23(10):1625-30. PubMed ID: 12376470
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis and Binding Affinity Evaluation of Cytochrome P450 1B1 Targeted Chelators.
Chen D; Fan Q; Xu T; Dong J; Cui J; Wang Z; Wang J; Meng Q; Li S
Anticancer Agents Med Chem; 2022; 22(2):261-269. PubMed ID: 33820523
[TBL] [Abstract][Full Text] [Related]
17. Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis.
Saini S; Hirata H; Majid S; Dahiya R
Cancer Res; 2009 Sep; 69(17):7038-45. PubMed ID: 19690133
[TBL] [Abstract][Full Text] [Related]
18. Cancer chemoprevention revisited: Cytochrome P450 family 1B1 as a target in the tumor and the microenvironment.
D'Uva G; Baci D; Albini A; Noonan DM
Cancer Treat Rev; 2018 Feb; 63():1-18. PubMed ID: 29197745
[TBL] [Abstract][Full Text] [Related]
19. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin.
Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F
Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010
[TBL] [Abstract][Full Text] [Related]
20. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.
Zhu Z; Mu Y; Qi C; Wang J; Xi G; Guo J; Mi R; Zhao F
Int J Mol Med; 2015 Feb; 35(2):340-8. PubMed ID: 25516145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
